+44 20 3868 9735
Objective: The aim of this prospective, double-blind, randomized, placebo-controlled clinical trial was to investigate the opioid-sparing effects of orally administered celecoxib following total abdominal hysterectomy. Methods: The study population consisted of 52 patients scheduled for total abdominal hysterectomy (TAH) who were ASA I or II physical status females. Patients were allocated randomly to orally receive 400 mg of celecoxib (Group C, n = 26) or placebo (Group P, n = 26) 1 hour before anesthesia induction. All patients underwent the same standard general anesthesia with oral intubation. Morphine was self-administered for postoperative analgesia via a patient controlled analgesia (PCA) device. Results: Only 1 patient did not complete the study. Of the remaining 51 patients, there was no significant difference between the treatment groups in age, weight, ASA status, duration of surgery, or intraoperative dose of morphine. However, the mean (95% CI) 24 h morphine consumption of 17.5 (11.9, 23.2) mg in the celecoxib group was not significantly lower than that of 24.2 (18.6, 29.7) mg in the placebo group (P=0.089). There were no significant differences between groups in morphine consumption, initial analgesic requirement, and numeric rating scores for pain at rest or on movement, nausea or sedation during the first 24 hours after operation. Conclusion: We conclude that preemptive celecoxib did not confer additional analgesia in patients undergoing total abdominal hysterectomy.